middle.news
How Dimerix’s US$30M Amicus Deal Could Transform Kidney Disease Treatment
8:44am on Friday 25th of July, 2025 AEST
•
Healthcare
Read Story
How Dimerix’s US$30M Amicus Deal Could Transform Kidney Disease Treatment
8:44am on Friday 25th of July, 2025 AEST
Key Points
Exclusive US license deal with Amicus Therapeutics for DMX-200
Up to US$590 million in upfront, milestone payments, and royalties
Over AU$65 million received from four licensing deals to date
FDA accepts proteinuria as primary endpoint for US approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE